Pass the ACRP Certified Professional ACRP-CP Questions and answers with ValidTests

Risk reduction activities fall underRisk Controlwithin a Quality Management System (QMS). Risk control involves implementing measures to reduce identified risks to an acceptable level, including corrective actions, preventive measures, and continuous monitoring. It aims to mitigate potential negative impacts on trial integrity and participant safety.

GCP guidelines highlight that risk control encompasses actions taken to minimize the likelihood and impact of identified risks.

"Risk control is the process of implementing measures to mitigate risks identified during the risk assessment phase."

Objectives:

Implement effective risk management strategies.

Ensure proactive risk mitigation in clinical trials.

Since the protocol specifies that participants withdrawn due to an Adverse Event (AE) should not bereplaced, only the participants withdrawn for noncompliance (3 in total) should be replaced. The participant who withdrew consent due to severe nausea (an AE) and the one who discontinued IP due to hospitalization should not be replaced.

GCP guidelines specify that replacement of subjects should follow the protocol criteria, particularly when AEs are involved.

"Participants withdrawn due to AEs should not be replaced if the protocol stipulates this condition, while noncompliant participants may be replaced."

Objectives:

Follow protocol guidelines for participant replacement.

Ensure compliance with study criteria.

The primary factor in determining whether a protocol deviation should be reported to the IRB/IEC is whether the deviation impacts participant safety or the integrity of the study data. Any deviation that could pose a risk to participants must be reported promptly to ensure ongoing ethical oversight.

GCP guidelines mandate reporting of any protocol deviations that affect safety or data integrity to the IRB/IEC.

"Protocol deviations that impact the safety of participants or the integrity of the study must be reported to the IRB/IEC."

Objectives:

Maintain participant safety.

Ensure regulatory compliance through prompt reporting.

The frequency of data backup is a critical element of an Electronic Data Capture (EDC) system's Standard Operating Procedure (SOP). Ensuring regular and systematic data backup is essential for protecting trial data against loss or corruption. Failure to specify backup frequency indicates a gap in data security management.

GCP guidelines stress that data protection, including regular backups, is essential to maintaining data integrity in clinical trials.

"EDC system SOPs must include clear guidelines on data backup frequency to safeguard the integrity and availability of study data."

Objectives:

Ensure data security through regular backups.

Maintain data integrity in clinical research.

Interim analysis should be reviewed by independent qualified individuals, such as members of a Data Safety Monitoring Board (DSMB) or Independent Data Monitoring Committee (IDMC). This ensures that the analysis is unbiased and that decisions regarding continuation, modification, or termination of the trial are made objectively.

GCP guidelines emphasize that interim data should be reviewed by an independent committee to prevent bias and ensure participant safety.

"Interim analyses should be conducted by independent experts to maintain objectivity and safeguard trial integrity."

Objectives:

Maintain impartiality during interim analysis.

Ensure unbiased decision-making regarding trial continuation.

In investigator-initiated studies, the PI holds primary responsibility for addressing non-compliance, including root cause analysis and implementation of CAPA plans. This ensures that any issues affecting the study’s integrity are adequately addressed and prevented in the future.

The answer is verified based on ICH E6(R2) guidelines which emphasize the PI’s responsibility for maintaining compliance at the study site.

"The PI must develop and implement corrective and preventive actions when non-compliance is identified during the study."

Objectives:

Maintain compliance in investigator-initiated studies.

Address non-compliance through CAPA.

Risk-based monitoring focuses on adapting the frequency and intensity of on-site visits based on data quality and site performance. If the data is consistently accurate and reliable, the monitoring frequency may be reduced. Conversely, if issues are identified, more frequent monitoring may be necessary.

GCP guidelines emphasize a flexible approach to monitoring, allowing adjustments based on the risk profile and quality of data collected.

"Risk-based monitoring involves adapting the frequency of on-site visits according to the quality of the data and the site's compliance level."

Objectives:

Implement a dynamic monitoring strategy.

Enhance efficiency while maintaining data integrity.

A Corrective and Preventive Action (CAPA) plan is implemented to address deviations and prevent them from recurring. In this context, the purpose of the CAPA is to establish a procedure for the Principal Investigator (PI) to ensure proper oversight of protocol deviations. This ensures that all future deviations are appropriately managed, reviewed, and documented according to GCP standards.

The answer is verified from GCP guidelines which emphasize that CAPA should focus on identifying root causes and establishing processes to prevent future deviations.

"A CAPA plan must address the root cause and implement systematic actions to prevent the recurrence of protocol deviations."

Objectives:

Ensuring PI oversight in protocol adherence

Maintaining data integrity through systematic corrective actions

Root cause analysis (RCA) is a systematic process aimed at identifying the underlying reasons for non-compliance or errors in clinical trials. The purpose of RCA is to understand why a problem occurred so that corrective and preventive actions (CAPA) can be implemented effectively. Focusing on issues of non-compliance ensures that the study adheres to GCP and regulatory requirements.

GCP guidelines recommend performing a root cause analysis when deviations or non-compliance are identified to develop effective CAPA plans.

"Root cause analysis focuses on identifying non-compliance issues to implement corrective and preventive measures effectively."

Objectives:

Address non-compliance systematically.

Develop effective CAPA plans.

During the IRB/IEC review process, only members who actively participated in the review and discussion are eligible to vote. This ensures that votes are cast by those who are adequately informed about the study and can make an educated decision. Non-member experts may participate in discussions but do not have voting rights.

GCP guidelines state that voting rights in IRB/IEC meetings are limited to members who have thoroughly reviewed and discussed the study, maintaining unbiased and informed decision-making.

"Only IRB/IEC members who were involved in the review and discussion should participate in the voting process."

Objectives:

Ensure informed voting in ethical review processes.

Maintain integrity and objectivity in IRB/IEC decisions.